当前位置:首页 - 行情中心 - 百诚医药(301096) - 财务分析 - 现金流量表

百诚医药

(301096)

  

流通市值:36.28亿  总市值:47.68亿
流通股本:8311.46万   总股本:1.09亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金220,526,361.6499,846,567.09404,491,154.76237,057,558.97
  收到的税费返还8,220,440.73-34,063.64-
  收到其他与经营活动有关的现金25,334,750.6518,568,665.5130,031,195.6216,775,420.52
  经营活动现金流入小计254,081,553.02118,415,232.6434,556,414.02253,832,979.49
  购买商品、接受劳务支付的现金74,582,955.8632,496,586.33210,575,468.36173,731,984.45
  支付给职工以及为职工支付的现金122,050,361.1161,550,794.66269,492,748.92210,960,922.9
  支付的各项税费6,699,439.426,583,819.4211,740,535.2410,504,504.01
  支付其他与经营活动有关的现金55,635,556.4124,635,112.2597,392,351.3938,421,185.35
  经营活动现金流出小计258,968,312.8125,266,312.66589,201,103.91433,618,596.71
  经营活动产生的现金流量净额-4,886,759.78-6,851,080.06-154,644,689.89-179,785,617.22
二、投资活动产生的现金流量:
  收回投资收到的现金2,601,923.082,150,0004,335,622.58-
  处置固定资产、无形资产和其他长期资产收回的现金净额--423,095.56289,098.86
  收到的其他与投资活动有关的现金32,756,160.4329,556,160.43413,746,697.38308,244,674.62
  投资活动现金流入小计35,358,083.5131,706,160.43418,505,415.52308,533,773.48
  购建固定资产、无形资产和其他长期资产支付的现金62,491,048.3241,090,198.5397,917,790.1184,160,403.38
  投资支付的现金4,640,000-34,870,00016,634,377.42
  支付其他与投资活动有关的现金6,893,878.519,483,548.32406,522,985.01396,221,684
  投资活动现金流出小计74,024,926.8350,573,746.85539,310,775.12497,016,464.8
  投资活动产生的现金流量净额-38,666,843.32-18,867,586.42-120,805,359.6-188,482,691.32
三、筹资活动产生的现金流量:
  取得借款收到的现金460,000,000290,000,0001,061,282,342.62816,782,342.6
  收到其他与筹资活动有关的现金-411,113.1--
  筹资活动现金流入小计460,000,000290,411,113.11,061,282,342.62816,782,342.6
  偿还债务支付的现金356,711,527.78152,961,527.78899,878,047.62491,582,342.6
  分配股利、利润或偿付利息支付的现金10,684,720.94,975,481.0820,521,855.4715,768,956.1
  支付其他与筹资活动有关的现金1,576,287.96258,029.621,039,056.57524,223.68
  筹资活动现金流出小计368,972,536.64158,195,038.48921,438,959.66507,875,522.38
  筹资活动产生的现金流量净额91,027,463.36132,216,074.62139,843,382.96308,906,820.22
四、汇率变动对现金及现金等价物的影响-9,887.73-2,550.9-78,180.21312,756.01
五、现金及现金等价物净增加额47,463,972.53106,494,857.24-135,684,846.74-59,048,732.31
  加:期初现金及现金等价物余额280,476,499.32280,476,499.32416,161,346.06416,161,346.06
  期末现金及现金等价物余额327,940,471.85386,971,356.56280,476,499.32357,112,613.75
补充资料:
  净利润1,593,651.56--90,395,530.08-
  资产减值准备10,724,767.59-33,684,968.18-
  固定资产和投资性房地产折旧80,223,870.65-153,346,776.61-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧80,223,870.65-153,346,776.61-
  无形资产摊销1,655,984.64-3,615,183.44-
  长期待摊费用摊销335,467.94-582,129.27-
  处置固定资产、无形资产和其他长期资产的损失-221,017.11--218,302.93-
  固定资产报废损失1,317.82-1,088.29-
  财务费用11,267,862.04-21,176,464.26-
  投资损失-4,857,802.1-11,796,809.44-
  递延所得税-869,204.5--1,317,235.31-
  其中:递延所得税资产减少-869,204.5--1,317,235.31-
  存货的减少-18,790,513.73--5,644,593.86-
  经营性应收项目的减少-83,354,090.92--211,649,108.73-
  经营性应付项目的增加-3,028,600.62--71,930,986.37-
  其他--1,625,076.39-
  现金的期末余额327,940,471.85-280,476,499.32-
  减:现金的期初余额280,476,499.32-416,161,346.06-
  现金及现金等价物的净增加额47,463,972.53--135,684,846.74-
公告日期2026-08-272026-04-242026-04-242025-10-25
审计意见(境内)标准无保留意见
TOP↑